JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB320829

Anti-FGF19 抗体 [EPR29017-89]

Anti-FGF19 antibody [EPR29017-89]

  • BOND RX™ Validated
  • 20ul selling size
  • Recombinant
  • RabMAb
  • 詳細を見る

Be the first to review this product! Submit a review

|

(0 Publication)

Rabbit Recombinant Monoclonal FGF19 antibody. Suitable for WB, IHC-P and reacts with Human samples.

別名を表示する

UNQ334/PRO533, FGF19, Fibroblast growth factor 19, FGF-19

6 Images
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FGF19 antibody [EPR29017-89] (AB320829)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FGF19 antibody [EPR29017-89] (AB320829)

Immunohistochemical analysis of paraffin-embedded Human colon tissue labeling FGF19 with ab320829 at 1/2000 (0.254 ug/ml) dilution, followed by a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection).

Negative control : no staining on human colon (PMID : 37345586, 36923538).
The section was incubated with ab320829 for 30 mins at room temperature.
The immunostaining was performed on a Leica Biosystems BOND® RX instrument

Counterstained with Hematoxylin.

Secondary antibody only control : Secondary antibody is a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection).

Heat mediated antigen retrieval was performed with Tris-EDTA buffer (pH 9.0, Epitope Retrieval Solution2) for 20 mins

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FGF19 antibody [EPR29017-89] (AB320829)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FGF19 antibody [EPR29017-89] (AB320829)

Immunohistochemical analysis of paraffin-embedded Human liver tissue labeling FGF19 with ab320829 at 1/2000 (0.254 ug/ml) dilution, followed by a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection).

Negative control : no staining on human liver (PMID : 31976601).
The section was incubated with ab320829 for 30 mins at room temperature.
The immunostaining was performed on a Leica Biosystems BOND® RX instrument

Counterstained with Hematoxylin.

Secondary antibody only control : Secondary antibody is a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection).

Heat mediated antigen retrieval was performed with Tris-EDTA buffer (pH 9.0, Epitope Retrieval Solution2) for 20 mins

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FGF19 antibody [EPR29017-89] (AB320829)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FGF19 antibody [EPR29017-89] (AB320829)

Immunohistochemical analysis of paraffin-embedded Human endometrial carcinoma tissue labeling FGF19 with ab320829 at 1/2000 (0.254 ug/ml) dilution, followed by a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection).

Positive staining on human endometrial carcinoma.
The section was incubated with ab320829 for 30 mins at room temperature.
The immunostaining was performed on a Leica Biosystems BOND® RX instrument

Counterstained with Hematoxylin.

Secondary antibody only control : Secondary antibody is a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection).

Heat mediated antigen retrieval was performed with Tris-EDTA buffer (pH 9.0, Epitope Retrieval Solution2) for 20 mins

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FGF19 antibody [EPR29017-89] (AB320829)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FGF19 antibody [EPR29017-89] (AB320829)

Immunohistochemical analysis of paraffin-embedded Human gall bladder tissue labeling FGF19 with ab320829 at 1/2000 (0.254 ug/ml) dilution, followed by a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection).

Positive staining on epthelium of human gall bladder (PMID : 26256900).
The section was incubated with ab320829 for 30 mins at room temperature.
The immunostaining was performed on a Leica Biosystems BOND® RX instrument

Counterstained with Hematoxylin.

Secondary antibody only control : Secondary antibody is a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection).

Heat mediated antigen retrieval was performed with Tris-EDTA buffer (pH 9.0, Epitope Retrieval Solution2) for 20 mins

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FGF19 antibody [EPR29017-89] (AB320829)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FGF19 antibody [EPR29017-89] (AB320829)

Immunohistochemical analysis of paraffin-embedded (A) SW480 (human colorectal adenocarcinoma epithelial cell) cell pellet; (B) HL-60 (human acute promyelocytic leukemia promyeloblast) cell pellet tissue labeling FGF19 with ab320829 at 1/2000 (0.254 ug/ml) dilution, followed by a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection).

Positive staining on (A) SW480 cell pellet; no staining on (B) HL-60 cell pellet.
The section was incubated with ab320829 for 30 mins at room temperature.
The immunostaining was performed on a Leica Biosystems BOND® RX instrument

Counterstained with Hematoxylin.

Secondary antibody only control : Secondary antibody is a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection).

Heat mediated antigen retrieval was performed with Tris-EDTA buffer (pH 9.0, Epitope Retrieval Solution2) for 20 mins

Western blot - Anti-FGF19 antibody [EPR29017-89] (AB320829)
  • WB

Supplier Data

Western blot - Anti-FGF19 antibody [EPR29017-89] (AB320829)

Blocking and diluting buffer and concentration : 5% NFDM/TBST.

Negative control : HL-60, HeLa, K-562, 293T (PMID : 10525310)

In Western blot, Anti-GAPDH antibody [EPR16891] - Loading Control (ab181602) staining at 1/200000 dilution.

All lanes:

Western blot - Anti-FGF19 antibody [EPR29017-89] (ab320829) at 1/1000 dilution

Lane 1:

SW480 (human colorectal adenocarcinoma epithelial cell) whole cell lysate at 20 µg

Lane 2:

COLO1 (human colon adenocarcinoma tumor ascitic fibroblast-like cell) whole cell lysate at 20 µg

Lane 3:

HL-60 (human acute promyelocytic leukemia promyeloblast) whole cell lysate at 20 µg

Lane 4:

HeLa (human cervical adenocarcinoma epithelial cell) whole cell lysate at 20 µg

Lane 5:

K-562 (human chronic myelogenous leukemia lymphoblast) whole cell lysate at 20 µg

Lane 6:

293T (human embryonic kidney epithelial cell) whole cell lysate at 20 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution

Observed band size: 24 kDa,36 kDa

false

Exposure time: 37s

Key facts

宿主種

Rabbit

クローン性

Monoclonal

クローン番号

EPR29017-89

アイソタイプ

IgG

キャリアフリー

No

交差種

Human

アプリケーション

WB, IHC-P

applications

免疫原

The exact immunogen used to generate this antibody is proprietary information.

style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "<p></p>", "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/2000", "IHCP-species-notes": "<p></p> Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol." } } }
style
left-column

製品の詳細

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

style
left-column

出荷温度及び保存条件

製品の状態
Liquid
精製方法
Affinity purification Protein A
バッファー組成
pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
出荷温度
Blue Ice
短期保存期間
1-2 weeks
短期保存温度
+4°C
長期保存温度
-20°C
分注に関する情報
Upon delivery aliquot
保管に関する情報
Avoid freeze / thaw cycle
style
left-column

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

FGF19 also known as fibroblast growth factor 19 is a 251 amino acid protein with a molecular mass of approximately 27 kDa. It is mostly expressed in the liver small intestine and to some extent in the gallbladder. FGF19 is related to the FGF family of growth factors which are involved in a variety of developmental and physiological processes. Unlike many other FGF members FGF19 lacks a heparin-binding domain which influences its receptor binding characteristics. Researchers frequently use FGF19 ELISA kits and FGF19 assays to study this protein due to its significance in regulating bile acid metabolism.
Biological function summary

Fibroblast growth factor 19 participates in maintaining metabolic homeostasis and controlling bile acid synthesis. It acts by binding to a receptor complex composed of FGFR4 and beta-Klotho which signals the regulation of energy balance and interaction with other metabolic targets. FGF19 protein triggers pathways that modulate glucose and lipid metabolism making it an important factor in metabolic health. Its regulation of lipid and glucose processes emphasizes its role in metabolic control systems and potential impacts on obesity and diabetes management.

Pathways

The fibroblast growth factor 19 engages in two critical signaling routes: the MAPK/ERK and the PI3K/AKT pathways. These pathways are fundamental in cell proliferation differentiation and survival. FGF19 through FGFR4 activation influences regulatory proteins and factors downstream bridging interactions with other key molecules such as insulin and leptin pathways. This regulatory mechanism contributes to its ability to fine-tune a wide range of metabolic functions and influences energy balance.

Fibroblast growth factor 19 shows a significant connection to non-alcoholic fatty liver disease (NAFLD) and certain forms of cancer. Altered expression levels of FGF19 associate with liver conditions due to its role in bile acid regulation and energy homeostasis. In cancer particularly hepatocellular carcinoma the dysregulation of FGF19 and its receptor plays a part in unchecked cellular proliferation and tumorigenesis. Researchers have noted connections with proteins such as FGFR4 and beta-Klotho highlighting their collaborative roles in disease progression and potential therapeutic targeting strategies.
style
left-column
style
left-column

製品プロトコール

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

ターゲットの情報

Involved in the suppression of bile acid biosynthesis through down-regulation of CYP7A1 expression, following positive regulation of the JNK and ERK1/2 cascades. Stimulates glucose uptake in adipocytes. Activity requires the presence of KLB and FGFR4.
See full target information FGF19
style
left-column
style
left-column
style
right-column

Complementary Products

Assay Kits

AB230943

Human FGF19 ELISA Kit

Recombinant|SimpleStep

Sandwich ELISA - Human FGF19 ELISA Kit (AB230943)

  • 0
  • 0
Primary Antibodies

AB242608

Anti-CCL23 antibody [EPR19763-47] - BSA and Azide free (Capture)

RabMAb|Recombinant

Sandwich ELISA - Anti-CCL23 antibody [EPR19763-47] - BSA and Azide free (Capture) (AB242608)

  • 0
  • 0
Primary Antibodies

AB242990

Anti-EGF antibody [EPR19899-46] - BSA and Azide free (Detector)

RabMAb|Recombinant

Sandwich ELISA - Anti-EGF antibody [EPR19899-46] - BSA and Azide free (Detector) (AB242990)

  • 0
  • 0
Primary Antibodies

AB242545

Anti-MIP-1 alpha/CCL3 + CCL4/MIP-1 beta antibody [EPR19900-275] - BSA and Azide free (Capture)

RabMAb|Recombinant

Sandwich ELISA - Anti-MIP-1 alpha/CCL3 + CCL4/MIP-1 beta antibody [EPR19900-275] - BSA and Azide free (Capture) (AB242545)

  • 0
  • 0
Primary Antibodies

AB259496

Anti-CCL25 antibody [EPR21835-289] - BSA and Azide free (Detector)

RabMAb|Recombinant

Sandwich ELISA - Anti-CCL25 antibody [EPR21835-289] - BSA and Azide free (Detector) (AB259496)

  • 0
  • 0

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。
保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com